search
Back to results

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PROJECT-BARI)

Primary Purpose

Obesity

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Topiramate
Phentermine
Placebo
Sponsored by
University of California, Irvine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Bariatric surgery, Weight regain, Antiobesity drugs, Treatment of weight regain

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male and female subjects aged 18-70 years Had sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) between ≥18 months and ≤10 years ago Weight regain of ≥5% relative to post-surgery nadir weight Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidities Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry Must be able to provide written informed consent Exclusion Criteria: Type 1 diabetes Insulin-dependent type 2 diabetes Fasting plasma glucose (FPG) ≥240 mg/dL Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥100 mm Hg on the average of three seated measurements after being at rest for at least 5 minutes History of significant (as determined by the investigator) and unstable cardiovascular disease including coronary artery disease, arrhythmias, severe congestive heart failure, or stroke Use of monoamine oxidase inhibitors, current or within 2 weeks Hyperthyroidism or other significant thyroid disease Angle-closure glaucoma Agitated states History of drug abuse within the past year Known hypersensitivity or idiosyncrasy to sympathomimetic amines Severe hepatic disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis without portal hypertension or cirrhosis is acceptable) End-stage renal disease History of nephrolithiasis Serum triglycerides ≥500 mg/dL Cancer, not in remission, within the past 2 years except for adequately treated basal cell, squamous cell skin cancer, or in-situ cervical cancer History of psychosis or bipolar disorder Suicidal ideation or unstable/untreated major depressive disorder within the past year Use of antidepressant medication that has not been at stable dose for at least 3 months Hospital Anxiety and Depression Scale (HADS) score of ≥11 for depression or anxiety items Binge Eating Scale (BES) score of ≥27 Alcohol use disorder within the past year Epilepsy Currently taking phentermine or topiramate or the combination, or products containing these drugs Currently taking stimulants (e.g., Attention Deficit Hyperactivity Disorder medications) Current use of prescription or over-the-counter weight loss drugs or supplements Taking prescription or over-the-counter drugs or products, which in the opinion of the PI, could be associated with significant effects on body weight Planning additional bariatric surgery procedures in the next 13 months History of revisional bariatric surgery (revisional surgery after adjustable gastric banding is acceptable) Currently participating in another weight loss program or have plans to participate in the next 13 months Smoking cessation within the previous 3 months or plans to quit smoking in the next 13 months Pregnant or breastfeeding or planning pregnancy in the coming 13 months History of, or any existing condition that, in the opinion of the Principal Investigator, would interfere with the study outcomes or place the subject at unacceptable risk by participating in the study

Sites / Locations

  • University of California Irvine Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Group A: Topiramate 50 mg

Group B: Topiramate 100 mg

Group C: Phentermine 7.5 mg/Topiramate 50 mg

Group D: Phentermine 7.5 mg

Group E: Phentermine 15 mg

Group F: Phentermine 7.5 mg/Topiramate 50 mg

Group P: Placebo

Arm Description

Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.

Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.

Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.

Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.

Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.

Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12. For Group F, topiramate will be dosed at 25 mg daily for the 15 days in Month 5 and 50 mg daily thereafter,

Placebo group will receive placebo.

Outcomes

Primary Outcome Measures

Percent weight loss at Month 12 - Topiramate vs placebo
Topiramate (Group 1 [Group A + Group B]) vs placebo (Group P)
Percent weight loss at Month 12 - Phentermine vs placebo
Phentermine (Group 2 [Group D + Group E) vs placebo (Group P)
Percent weight loss at Month 12 - Phentermine/Topiramate
Phentermine/Topiramate (Group 3 [Group C + Group F]) vs placebo (Group P)

Secondary Outcome Measures

Energy intake
Change in energy intake in kcal/d assessed with a dietitian interview. Comparisons between Groups 1, 2, 3 vs placebo.

Full Information

First Posted
July 21, 2023
Last Updated
August 30, 2023
Sponsor
University of California, Irvine
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05975580
Brief Title
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
Acronym
PROJECT-BARI
Official Title
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 29, 2023 (Actual)
Primary Completion Date
April 2, 2027 (Anticipated)
Study Completion Date
July 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.
Detailed Description
Although bariatric surgery is the most effective treatment for severe obesity, a large proportion of patients experience significant weight regain with longer follow-up. In this randomized controlled trial employing a SMART design, a total of 120 subjects with weight regain after bariatric surgery, will be initially randomized in a 3:3:2 ratio to daily treatment with topiramate (TPM) 50 mg or phentermine (PHEN) 7.5 mg or placebo. After 4 months, responders (those with ≥5% weight loss) will continue the same treatment, while nonresponders will be re-randomized to a higher dose of the same drug or phentermine/topiramate 7.5/50 mg combination (PHEN/TPM) during Months 5-12. All subjects will receive diet and lifestyle counseling throughout the study. Aim 1: To determine whether pharmacotherapy can reverse post-bariatric surgery weight regain. Hypothesis: Compared to placebo, all three active drug therapies - TPM, PHEN, and PHEN/TPM will lead to greater percent weight loss at Month 12. Aim 2: To examine change in energy intake assessed by a dietitian interview. Hypothesis: Compared to placebo, active drug therapies will lead to greater reduction in energy intake at Month 12. Aim 3: To examine changes in the most common maladaptive eating behaviors in the post-bariatric surgery patients - grazing, loss-of-control eating, and binge eating. Hypothesis: Compared to placebo, active drug therapies will lead to decreased maladaptive eating behaviors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Bariatric surgery, Weight regain, Antiobesity drugs, Treatment of weight regain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Sequential Assignment
Model Description
A total of 120 eligible subjects, with weight regain after bariatric surgery, will be initially randomized in a 3:3:2 ratio to daily treatment with topiramate (TPM) 50 mg or phentermine (PHEN) 7.5 mg or placebo. After 4 months, responders (those with ≥5% weight loss) will continue the same treatment, while nonresponders will be re-randomized to a higher dose of the same drug or phentermine/topiramate 7.5/50 mg combination (PHEN/TPM) during Months 5-12. All randomized subjects will receive lifestyle counseling throughout the study.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The investigational drugs and placebo capsules will look identical. University of California Irvine Medical Center Investigational Drug Service will dispense the masked study drugs in accordance with randomization. The study statistician who generates the randomization scheme and the research pharmacist who dispenses the study drugs are the only personnel who are unblinded to the randomized assignment. Investigators and all other study personnel and the study subjects will be blinded to the treatment assignment until subjects have completed all visits, all data have been entered, and the data file has been locked.
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A: Topiramate 50 mg
Arm Type
Experimental
Arm Description
Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.
Arm Title
Group B: Topiramate 100 mg
Arm Type
Experimental
Arm Description
Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Arm Title
Group C: Phentermine 7.5 mg/Topiramate 50 mg
Arm Type
Experimental
Arm Description
Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Arm Title
Group D: Phentermine 7.5 mg
Arm Type
Experimental
Arm Description
Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.
Arm Title
Group E: Phentermine 15 mg
Arm Type
Experimental
Arm Description
Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Arm Title
Group F: Phentermine 7.5 mg/Topiramate 50 mg
Arm Type
Experimental
Arm Description
Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12. For Group F, topiramate will be dosed at 25 mg daily for the 15 days in Month 5 and 50 mg daily thereafter,
Arm Title
Group P: Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo group will receive placebo.
Intervention Type
Drug
Intervention Name(s)
Topiramate
Intervention Description
Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Intervention Type
Drug
Intervention Name(s)
Phentermine
Intervention Description
Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo is an inactive substance.
Primary Outcome Measure Information:
Title
Percent weight loss at Month 12 - Topiramate vs placebo
Description
Topiramate (Group 1 [Group A + Group B]) vs placebo (Group P)
Time Frame
Month 0, Month 12
Title
Percent weight loss at Month 12 - Phentermine vs placebo
Description
Phentermine (Group 2 [Group D + Group E) vs placebo (Group P)
Time Frame
Month 0, Month 12
Title
Percent weight loss at Month 12 - Phentermine/Topiramate
Description
Phentermine/Topiramate (Group 3 [Group C + Group F]) vs placebo (Group P)
Time Frame
Month 0, Month 12
Secondary Outcome Measure Information:
Title
Energy intake
Description
Change in energy intake in kcal/d assessed with a dietitian interview. Comparisons between Groups 1, 2, 3 vs placebo.
Time Frame
Month 0, Month 12
Other Pre-specified Outcome Measures:
Title
Grazing
Description
Change in grazing behavior, assessed with the Grazing Questionnaire. Comparisons between Groups 1, 2, 3 vs placebo.
Time Frame
Months 0, 4, 12
Title
Loss-of-control eating
Description
Change in loss-of-control eating, assessed with the Loss-of-Control Eating Scale. Comparisons between Groups 1, 2, 3 vs placebo.
Time Frame
Months 0, 4, 12
Title
Binge eating
Description
Change in binge eating, assessed with the Binge Eating Scale. Comparisons between Groups 1, 2, 3 vs placebo.
Time Frame
Months 0, 4, 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female subjects aged 18-70 years Had sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) between ≥18 months and ≤10 years ago Weight regain of ≥5% relative to post-surgery nadir weight Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidities Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry Must be able to provide written informed consent Exclusion Criteria: Type 1 diabetes Insulin-dependent type 2 diabetes Fasting plasma glucose (FPG) ≥240 mg/dL Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥100 mm Hg on the average of three seated measurements after being at rest for at least 5 minutes History of significant (as determined by the investigator) and unstable cardiovascular disease including coronary artery disease, arrhythmias, severe congestive heart failure, or stroke Use of monoamine oxidase inhibitors, current or within 2 weeks Hyperthyroidism or other significant thyroid disease Angle-closure glaucoma Agitated states History of drug abuse within the past year Known hypersensitivity or idiosyncrasy to sympathomimetic amines Severe hepatic disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis without portal hypertension or cirrhosis is acceptable) End-stage renal disease History of nephrolithiasis Serum triglycerides ≥500 mg/dL Cancer, not in remission, within the past 2 years except for adequately treated basal cell, squamous cell skin cancer, or in-situ cervical cancer History of psychosis or bipolar disorder Suicidal ideation or unstable/untreated major depressive disorder within the past year Use of antidepressant medication that has not been at stable dose for at least 3 months Hospital Anxiety and Depression Scale (HADS) score of ≥11 for depression or anxiety items Binge Eating Scale (BES) score of ≥27 Alcohol use disorder within the past year Epilepsy Currently taking phentermine or topiramate or the combination, or products containing these drugs Currently taking stimulants (e.g., Attention Deficit Hyperactivity Disorder medications) Current use of prescription or over-the-counter weight loss drugs or supplements Taking prescription or over-the-counter drugs or products, which in the opinion of the PI, could be associated with significant effects on body weight Planning additional bariatric surgery procedures in the next 13 months History of revisional bariatric surgery (revisional surgery after adjustable gastric banding is acceptable) Currently participating in another weight loss program or have plans to participate in the next 13 months Smoking cessation within the previous 3 months or plans to quit smoking in the next 13 months Pregnant or breastfeeding or planning pregnancy in the coming 13 months History of, or any existing condition that, in the opinion of the Principal Investigator, would interfere with the study outcomes or place the subject at unacceptable risk by participating in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Phuong Linh Huynh, MPH
Phone
7144566155
Email
plhuynh@hs.uci.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Qin Wang
Email
qinw15@hs.uci.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kishore M Gadde, MD
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Phuong Linh Huynh, MPH
Phone
714-456-6155
Email
plhuynh@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Qin Wang
Email
qinw15@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Kishore M Gadde, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36752995
Citation
Noria SF, Shelby RD, Atkins KD, Nguyen NT, Gadde KM. Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment. Curr Diab Rep. 2023 Mar;23(3):31-42. doi: 10.1007/s11892-023-01498-z. Epub 2023 Feb 8.
Results Reference
background

Learn more about this trial

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

We'll reach out to this number within 24 hrs